search
Back to results

Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population

Primary Purpose

Acquired Brain Injury

Status
Completed
Phase
Phase 2
Locations
Israel
Study Type
Interventional
Intervention
Methylphenidate
Sponsored by
Loewenstein Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acquired Brain Injury focused on measuring Acquired pediatric brain injury, Methylphenidate, Traumatic brain injury, Cerebrovascular event, Hypoxic ischemic brain injury, Function (ecologic)

Eligibility Criteria

4 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and female.
  2. Ages 4-18 years old.
  3. No contraindications for Methylphenidate treatment such as hypersensitivity, cardiac disturbances unbalanced seizures etc'.
  4. Informed consent given by their legal guardian.
  5. Acquired brain injury

Exclusion Criteria:

  1. Refusal to participate by either guardian or child.
  2. No attentional disturbances in a computed screening exam: "TOVA".
  3. Medical contraindications to treatment with Methylphenidate such as short QT syndrome.
  4. Side effects due to treatment with Methylphenidate.
  5. Under medical treatment of medications enhancing dopamine/ noradrenaline release such as Amantadine.
  6. Unable to participate in tasks planned due to severe motor or cognitive disabilities.

Sites / Locations

  • Loewenstein Rehabilitation Hospital Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Methylphenidate treatment

Control

Arm Description

On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage

On three different days each participant will be re-evaluated without recieveing Methylphenidate.

Outcomes

Primary Outcome Measures

Measure time (in minutes and seconds) and the amount of assistance needed (number of times each participant needed assistance) to complete the different tasks.
Measure the effect of Methylphenidate on function (in everyday tasks like dressing) of children with acquired brain injury

Secondary Outcome Measures

Full Information

First Posted
July 1, 2014
Last Updated
February 25, 2019
Sponsor
Loewenstein Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02227056
Brief Title
Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population
Official Title
Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
January 30, 2017 (Actual)
Study Completion Date
March 1, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Loewenstein Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to investigate the influence of Methylphenidate in pediatric acquired brain injury population, regarding ecologic (every day) function. It is hypothesized that the function with treatment will improve when compared to function without treatment in the same patient. Improvement is expected by shortening time of execution in each specific task and by reduction of the amount of assistance needed.
Detailed Description
Attention deficits in patients with acquired brain injury (ABI) are one of the most common cognitive disorders acquainted. Prevalence of attention deficits after cerebrovascular accident (CVA) varies between 20-58%, and after traumatic brain injury (TBI) may range up to 60% Methylphenidate (MPH) is a central nervous system (CNS) stimulant. In the CNS it increases release and blocks reuptake of dopamine and noradrenalin, resulting in increased synaptic and extracellular concentrations. Methylphenidate (MPH), act at the D1 and α2-adrenergic receptors to facilitate effects on prefrontal cortical modulation of attention and working memory .Methylphenidate has been used effectively and safely for treatment of attention deficit hyperactivity disorder for many decades. The use of Methylphenidate to enhance attention in disorders following TBI has been proposed as "rational pharmacotherapy". It demonstrated improvement in response speed, in adult patients with chronic TBI. In pediatric population suffering Acquired brain injury there are scarce works regarding methylphenidate short or long term efficacy. Since there are scarce reports altogether on Methylphenidate's effect in pediatric Acquired brain injury population and since the studies up to now examined the effectiveness in neuropsychological batteries we find it of interest to examine the effect of Methylphenidate in ecological tasks, thus achieving a better understanding of its possible effect in this subpopulation. STUDY ASSUMPTIONS: Methylphenidate has a proved safety profile in pediatric population suffering from primary attention deficit hyperactivity disorder or secondary attention deficit hyperactivity disorder . Methylphenidate has positive influence on attentional disorders in pediatric population suffering from Acquired brain injury in subacute and chronic phases. Methylphenidate can enhance function of children with attentional disturbances secondary to Acquired brain injury in different everyday tasks. Methylphenidate can improve learning in pediatric population suffering from secondary attention deficit hyperactivity disorder after Acquired brain injury, during subacute rehabilitation period. STUDY POPULATION: The study is designed to include up to 40 children, aged 4-18 years, suffering attentional disturbances secondary to Acquired Brain Injury (CVA, TBI, Anoxic brain injury, Central Nervous System infections). Participants will be children hospitalized (inpatient or outpatient) for rehabilitation in Loewenstein Rehabilitation Center Hospital, with no contraindications for Methylphenidate treatment after their legal guardian gave informed consent for participation. STUDY METHODS: Before inclusion each participant will undergo: ECG A screened computed exam to prove attentional disturbances with the Test of Variables of Attention (TOVA) test. Each participant will be tested on each task twice in two week's period: twice without treatment of Methylphenidate and twice with Methylphenidate treatment. Some participants will be retested after 7-14 days with no further treatment with Methylphenidate, in order to estimate if influence of the drug on function continues with no further treatment. Drug will be given at least an hour and not more than 2.5 hours before being tested. Drug dosage 0.3 milligram/kilo rounded to the nearest full milligram dosage will be given a total of 3 times: once before Test of Variables of Attention (TOVA) exam under Methylphenidate, and two other days while the participant is tested on the different tasks. Testing will be done in two hours of treatment session on different days. Each participant will undergo the following tasks, in a consecutive order: Dressing -T-shirt. Burden of care graded by scales of The Functional Independence Measure (FIM) or the Functional Independence Measure for Children (WeeFIM) according to age of participant. Puzzle construction. Two different puzzles to avoid a possibility of learning. Both the same level according to Sheridan's developmental norms. Mathematical age appropriate working sheet. Interactive social game such as memory game. On this task each participant will be scored according to number of reminders given for his round or inhibition and his emotional reaction to winning /loosing the game on a scale of 1-5, 1 being appropriate reaction, 5 being highest frustration. The Occupational therapist scoring the child's abilities and amount assistance needed will be blindfolded to the treatment (given or not). Performance data in each task will be collected with regard to duration for completion, amount of assistance needed, impulsivity, long term and short term attention etc, and statistically analyzed. Each participant (without Methylphenidate treatment) will serve as control to data collected in the same tasks completed under treatment with Methylphenidate .

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acquired Brain Injury
Keywords
Acquired pediatric brain injury, Methylphenidate, Traumatic brain injury, Cerebrovascular event, Hypoxic ischemic brain injury, Function (ecologic)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
34 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Methylphenidate treatment
Arm Type
Experimental
Arm Description
On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
Arm Title
Control
Arm Type
No Intervention
Arm Description
On three different days each participant will be re-evaluated without recieveing Methylphenidate.
Intervention Type
Drug
Intervention Name(s)
Methylphenidate
Other Intervention Name(s)
Ritalin
Intervention Description
On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
Primary Outcome Measure Information:
Title
Measure time (in minutes and seconds) and the amount of assistance needed (number of times each participant needed assistance) to complete the different tasks.
Description
Measure the effect of Methylphenidate on function (in everyday tasks like dressing) of children with acquired brain injury
Time Frame
After each task is completed time of the specific task will be recorded. Each participant will be tested 6 times 45 minutes during 3 weeks and will be followed for duration of hospital stay an expected average of 1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female. Ages 4-18 years old. No contraindications for Methylphenidate treatment such as hypersensitivity, cardiac disturbances unbalanced seizures etc'. Informed consent given by their legal guardian. Acquired brain injury Exclusion Criteria: Refusal to participate by either guardian or child. No attentional disturbances in a computed screening exam: "TOVA". Medical contraindications to treatment with Methylphenidate such as short QT syndrome. Side effects due to treatment with Methylphenidate. Under medical treatment of medications enhancing dopamine/ noradrenaline release such as Amantadine. Unable to participate in tasks planned due to severe motor or cognitive disabilities.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sharon Shaklai, Dr
Organizational Affiliation
Loewenstein Hospital Rehabilitation Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sigal Greenbaum, Master
Organizational Affiliation
Loewenstein Hospital Rehabiltation Center
Official's Role
Study Director
Facility Information:
Facility Name
Loewenstein Rehabilitation Hospital Center
City
Raanana
ZIP/Postal Code
43100
Country
Israel

12. IPD Sharing Statement

Citations:
PubMed Identifier
19060022
Citation
Willmott C, Ponsford J. Efficacy of methylphenidate in the rehabilitation of attention following traumatic brain injury: a randomised, crossover, double blind, placebo controlled inpatient trial. J Neurol Neurosurg Psychiatry. 2009 May;80(5):552-7. doi: 10.1136/jnnp.2008.159632. Epub 2008 Dec 5.
Results Reference
background
PubMed Identifier
9689233
Citation
Hornyak JE, Nelson VS, Hurvitz EA. The use of methylphenidate in paediatric traumatic brain injury. Pediatr Rehabil. 1997 Jan-Mar;1(1):15-7. doi: 10.3109/17518429709060937.
Results Reference
background
PubMed Identifier
9431261
Citation
Whyte J, Hart T, Schuster K, Fleming M, Polansky M, Coslett HB. Effects of methylphenidate on attentional function after traumatic brain injury. A randomized, placebo-controlled trial. Am J Phys Med Rehabil. 1997 Nov-Dec;76(6):440-50. doi: 10.1097/00002060-199711000-00002.
Results Reference
background
PubMed Identifier
15166683
Citation
Whyte J, Hart T, Vaccaro M, Grieb-Neff P, Risser A, Polansky M, Coslett HB. Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil. 2004 Jun;83(6):401-20. doi: 10.1097/01.phm.0000128789.75375.d3.
Results Reference
background
PubMed Identifier
22020351
Citation
Wheaton P, Mathias JL, Vink R. Impact of pharmacological treatments on cognitive and behavioral outcome in the postacute stages of adult traumatic brain injury: a meta-analysis. J Clin Psychopharmacol. 2011 Dec;31(6):745-57. doi: 10.1097/JCP.0b013e318235f4ac.
Results Reference
background
PubMed Identifier
9838263
Citation
Mahalick DM, Carmel PW, Greenberg JP, Molofsky W, Brown JA, Heary RF, Marks D, Zampella E, Hodosh R, von der Schmidt E 3rd. Psychopharmacologic treatment of acquired attention disorders in children with brain injury. Pediatr Neurosurg. 1998 Sep;29(3):121-6. doi: 10.1159/000028705.
Results Reference
background

Learn more about this trial

Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population

We'll reach out to this number within 24 hrs